ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

NCT02044120 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Ewing Sarcoma

Interventions

DRUG: niraparib
DRUG: Temozolomide
DRUG: Irinotecan

Sponsor

Sarcoma Alliance for Research through Collaboration